Cocrystal Pharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
COCP$1.11+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash | $2,169 | $7,025 |
| Restricted cash | 75 | 75 |
| Government contract receivable | 35 | - |
| Tax credit receivable | 701 | 706 |
| Prepaid expenses and other current assets | 256 | 328 |
| Total current assets | 3,236 | 8,134 |
| Property and equipment, net | 69 | 93 |
| Deposits | 114 | 95 |
| Operating lease right-of-use assets, net (including $75 and $152 to related party) | 1,230 | 1,390 |
| Total assets | $4,649 | $9,712 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $2,264 | $1,876 |
| Current maturities of operating lease liabilities (including $60 and $49 to related party) | 352 | 334 |
| Total current liabilities | 2,616 | 2,210 |
| Long-term liabilities: | ||
| Operating lease liabilities (including $16 and $104 to related party) | 989 | 1,171 |
| Total long-term liabilities | 989 | 1,171 |
| Total liabilities | 3,605 | 3,381 |
| Commitments and contingencies | - | - |
| Stockholders’ equity: | ||
| Common stock, $0.001 a par value: 100,000 shares authorized as of June 30, 2026, and December 31, 2025; 13,789 and 13,784 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 13 | 13 |
| Additional paid-in capital | 348,743 | 348,567 |
| Accumulated deficit | (347,712) | (342,249) |
| Total stockholders’ equity | 1,044 | 6,331 |
| Total liabilities and stockholders’ equity | $4,649 | $9,712 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.